new YORK (Reuters Health) – the American College of

obstetricians and Gynecologists (ACOG, for its acronym in English) ensures

that a new version of the pill would elevate something

more risk of developing a clot than versions

above, although that risk is still low.

on new guides, this Panel of Experts recommends that

women are aware that “minimally high potential risk”

OCs with drospirenone, as Yaz,

Yasmin, Beyaz and Safyral, along with their versions generic.

it is known that users of the pill have a risk

low, but somewhat higher than the average of developing

clots and some studies have suggested that it is relatively

higher with pills with drospirenone.

but given “the weaknesses of studies”, unknown

If so, said Dr. Kavita Nanda, who participated in

the elaboration of the draft of the new guides of ACOG.

and the absolute risk of developing blood clots with

any oral contraceptive is low, according to ACOG in its

Journal Obstetrics & Gynecology. per each 10,000 users of

pills per year, would have between three and nine cases of

venous tromboembolias, compared with between one and five cases

for every 10,000 women who are not pregnant or use the

pill.

with the pill with drospirenone, some studies suggest

that there would be 10 cases for every 10,000 women per year.

venous thromboembolism usually occurs in the veins of the

legs, but can go up to the lungs, where a cause

embolism pulmonary.

drospirenone is a synthetic progesterone form

< p> different versions of earlier "generations" of the

pill. the advertising of Yasmin, which exists since makes a

decade, and products “Yaz” asserts that less fattening and

they produce less inflammation than the pills earlier.

“oral contraceptive with drospirenone also

would have advantages in women with acne or dysphoric syndrome

premenstrual”, said Nanda by e-mail to refer to a form

severe PMS that causes physical symptoms and disorders emotional.

previous studies the industry about Yasmin, Yaz and other

pills had not identified an increased risk of

clots to compare their formulas with those of other

pills. but several studies from the 2009 associated the

new contraceptives with a level of risk relatively more

high.

in a review of the histories of more than 800,000

womanVerenigde Staten, het beheer van voedsel en

geneesmiddelen in het land vonden dat voor elke 10.000 gebruikers van de

pil met intra bestaan ongeveer 10 gevallen van

thromboembolism venora per jaar, vergeleken met 6/10.000 gebruikers van

versies meer oude.

Bron: verloskunde en gynaecologie, November 2012